Related references
Note: Only part of the references are listed.Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation
Amin Huang et al.
CANCER LETTERS (2016)
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Naval Daver et al.
BLOOD (2015)
Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K
Rupert Courtnay et al.
MOLECULAR BIOLOGY REPORTS (2015)
Targeting FLT3 to treat leukemia
Heiko Konig et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway
P-P Liu et al.
CELL DEATH AND DIFFERENTIATION (2014)
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
Luis E. Raez et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis
Yumin Hu et al.
CELL RESEARCH (2012)
New agents for acute myeloid leukemia: is it time for targeted therapies?
Felicetto Ferrara
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
A translational study case report on the small molecule energy blocker 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside
Y. H. Ko et al.
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth
Daniela Gaglio et al.
MOLECULAR SYSTEMS BIOLOGY (2011)
FLT3 as a therapeutic target in AML: still challenging after all these years
Thomas Kindler et al.
BLOOD (2010)
A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
Joline S. W. Lind et al.
CLINICAL CANCER RESEARCH (2010)
Signal transduction to the permeability transition pore
Andrea Rasola et al.
FEBS LETTERS (2010)
Targeting Tumor Metabolism With 2-Deoxyglucose in Patients With Castrate-Resistant Prostate Cancer and Advanced Malignancies
Mark Stein et al.
PROSTATE (2010)
Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate
Zhao Chen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2009)
Mechanisms of resistance to FLT3 inhibitors
S. Haihua Chu et al.
DRUG RESISTANCE UPDATES (2009)
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML
Ellen Weisberg et al.
DRUG RESISTANCE UPDATES (2009)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
The Warburg effect and its cancer therapeutic implications
Zhao Chen et al.
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES (2007)
Antitumor activity of sorafenib in FLT3-driven leukemic cells
D. Auclair et al.
LEUKEMIA (2007)
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD
Jennifer L. Rocnik et al.
BLOOD (2006)
Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria
S. P. Mathupala et al.
ONCOGENE (2006)
Ras-dependent carbon metabolism and transformation in mouse broblasts
F. Chiaradonna et al.
ONCOGENE (2006)
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myelold transformation
CH Brandts et al.
CANCER RESEARCH (2005)
Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor β signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model
L Xu et al.
CANCER RESEARCH (2005)
Detection of resistance to imatinib by metabolic profiling - Clinical and drug development implications
N Serkova et al.
AMERICAN JOURNAL OF PHARMACOGENOMICS (2005)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability
O Vafa et al.
MOLECULAR CELL (2002)
Bax releases cytochrome c preferentially from a complex between porin and adenine nucleotide translocator. Hexokinase activity suppresses this effect.
MY Vyssokikh et al.
MOLECULAR BIOLOGY REPORTS (2002)
Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation
KF Tse et al.
LEUKEMIA (2000)
Share Paper
